These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 2117286

  • 1. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
    Marumo K, Tazaki H.
    Prog Clin Biol Res; 1990; 350():263-73. PubMed ID: 2117286
    [No Abstract] [Full Text] [Related]

  • 2. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P, Vitté-Mony I, Farace F, Stancou R, Triebel F, Escudier B, Hercend T, Bertoglio J.
    Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
    [No Abstract] [Full Text] [Related]

  • 3. Cyclic interferon gamma application in patients with renal cell carcinoma.
    Grups JW, Frohmüller HG.
    Prog Clin Biol Res; 1990; 350():257-62. PubMed ID: 2117285
    [No Abstract] [Full Text] [Related]

  • 4. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG, Younes E, Visscher D, Hamzavi F, Kim S, Lam JS, Montecillo EJ, Ali E, Pontes JE, Puri RK, Haas GP.
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [Abstract] [Full Text] [Related]

  • 5. New prospects in the management of metastatic renal cell carcinoma. Experimental and clinical data.
    Debruyne FM, Franssen MP, Beniers AJ, Schalken JA, de Mulder PH.
    Prog Clin Biol Res; 1990 Oct; 350():243-55. PubMed ID: 2117284
    [No Abstract] [Full Text] [Related]

  • 6. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
    Holdener EE, Emmons RP, Brunda M, Evans L, Levitt D.
    Prog Clin Biol Res; 1990 Oct; 348():61-9. PubMed ID: 2201034
    [No Abstract] [Full Text] [Related]

  • 7. The antitumor effects of IFN- beta against human renal cell carcinoma in athymic nude mice.
    Shirahama T, Kayajima T, Ohi Y.
    In Vivo; 1989 Oct; 3(5):345-9. PubMed ID: 2519876
    [Abstract] [Full Text] [Related]

  • 8. Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trials.
    Otto U, Schneider AW, Conrad S, Klosterhalfen H.
    Prog Clin Biol Res; 1990 Oct; 350():275-82. PubMed ID: 2117287
    [No Abstract] [Full Text] [Related]

  • 9. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
    Favrot M, Capdeville R, Combaret V, Zhou DC, Clapisson G, Banchereau J, Franks CR, Chouaib S, Blay JY, Philip T.
    Eur Cytokine Netw; 1990 Oct; 1(3):141-7. PubMed ID: 2129798
    [Abstract] [Full Text] [Related]

  • 10. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
    Kroeze SG, Daenen LG, Nijkamp MW, Roodhart JM, de Gast GC, Bosch JL, Jans JJ.
    J Urol; 2012 Aug; 188(2):607-14. PubMed ID: 22704448
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard JJ, Lesimple T, Catros-Quemener V.
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [Abstract] [Full Text] [Related]

  • 12. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG.
    APMIS Suppl; 1993 Jun; 35():1-26. PubMed ID: 8251200
    [No Abstract] [Full Text] [Related]

  • 13. Role of interleukin-2 alone in disseminated renal cell carcinoma: an update.
    Javadpour N, Lalehzarian M.
    Prog Clin Biol Res; 1989 Jun; 303():671-9. PubMed ID: 2789391
    [No Abstract] [Full Text] [Related]

  • 14. Are you prepared for interleukin-2?
    Muehlbauer PM, White RL.
    RN; 1998 Feb; 61(2):34-8; quiz 39. PubMed ID: 9485881
    [No Abstract] [Full Text] [Related]

  • 15. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT, Osgood B, Barna B, Boyett JM, Finke J, Medendorp SV, Murthy S, Novak C, Sergi J, Tubbs R.
    Cancer Res; 1989 Nov 15; 49(22):6432-6. PubMed ID: 2804986
    [Abstract] [Full Text] [Related]

  • 16. A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.
    Hum Gene Ther; 1992 Dec 15; 3(6):691-703. PubMed ID: 1482709
    [No Abstract] [Full Text] [Related]

  • 17. Interferons in renal-cell carcinoma: status and prospects.
    De Mulder PH, Debruyne FM, Beniers AJ.
    Prog Clin Biol Res; 1990 Dec 15; 348():49-59. PubMed ID: 1696737
    [No Abstract] [Full Text] [Related]

  • 18. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A, Muul LM, Rosenberg SA.
    Cancer Res; 1988 Jan 01; 48(1):206-14. PubMed ID: 3257161
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-2 antitumor and effector cell responses.
    Hawkins MJ.
    Semin Oncol; 1993 Dec 01; 20(6 Suppl 9):52-9. PubMed ID: 8284693
    [Abstract] [Full Text] [Related]

  • 20. Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma.
    Aso Y, Tazaki H, Umeda T, Marumo K.
    Prog Clin Biol Res; 1989 Dec 01; 303():681-8. PubMed ID: 2675018
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.